Adversarial Injection · Azathioprine (Imuran; CAS 446-86-6) NIOSH HD Category 1 / IARC Group 1 / OSHA No PEL / ACGIH No TLV / 6-MP Prodrug Glutathione Conversion OEL Architectural Gap / TPMT Pharmacogenomics / Transplant/Rheumatology Non-Oncology Pharmacy Dispensing Gap / Azathioprine+6-MP IARC Group 1 Thiopurine Null Chain · Attack #469

Azathioprine (Imuran; CAS 446-86-6; MW 277.26 g/mol; molecular formula C₉H₇N₇O₂S; 6-[(1-methyl-4-nitro-1H-imidazol-5-yl)thio]purine; thiopurine immunosuppressant; 1-methyl-4-nitroimidazole-5-thio-6-mercaptopurine; mechanism: non-enzymatic nucleophilic attack by glutathione [GSH] on the 5-nitroimidazole ring of azathioprine → scission of the thioether bond → release of 6-mercaptopurine [6-MP; CAS 50-44-2; Attack #456] + 5-mercapto-1-methyl-4-nitroimidazole [MNI]; 6-MP then undergoes TPMT [thiopurine methyltransferase; EC 2.1.1.67]-mediated methylation → 6-methylmercaptopurine [6-MMP; inactive] OR HPRT [hypoxanthine-guanine phosphoribosyltransferase]-mediated anabolism → 6-thioinosinic acid [6-TIMP] → 6-TGN [6-thioguanine nucleotides] → DNA incorporation → mismatch repair activation → cytotoxicity; TPMT pharmacogenomics: TPMT*3A/*3C poor metabolizers [3–7% European; ~24% reduced-activity heterozygotes] accumulate 3–10× more 6-TGN per identical azathioprine dose → myelosuppression and cytotoxicity; TPMT poor metabolizers exposed occupationally to azathioprine at same airborne concentration as normal metabolizers face disproportionately higher 6-TGN DNA accumulation; NIOSH: No REL — NIOSH Hazardous Drug Category 1 [2016 HD List]; OSHA: No PEL; ACGIH: No TLV; IARC: Group 1 [known human carcinogen; Monograph 100A, 2012; sufficient evidence: non-Hodgkin lymphoma + squamous cell carcinoma of skin in organ transplant recipients; H350 known carcinogen GHS]; GHS: H301+H311 H341 H350 H361 H372; Imuran brand [Prometheus Biosciences/Aspen Pharmacare; 50 mg azathioprine tablet; also 100 mg/20 mL IV injection]; used for: renal allograft rejection prophylaxis [post-transplant maintenance 1–3 mg/kg/day oral], rheumatoid arthritis [RA; 1–3 mg/kg/day oral], Crohn's disease and ulcerative colitis [IBD; 2–2.5 mg/kg/day oral], systemic lupus erythematosus [SLE], myasthenia gravis, systemic vasculitis; transplant/rheumatology non-oncology pharmacy dispensing gap: community pharmacies, rheumatologist office dispensaries, IBD clinic pharmacies, and GI specialty pharmacies fill azathioprine 50 mg tablet prescriptions for RA/IBD/SLE/MG patients using standard oral tablet counting procedures without USP 800 BSC gowning or NIOSH HD Category 1 protocols; ~400,000 US patients on azathioprine [2026 estimate across all indications]; azathioprine/6-MP IARC Group 1 thiopurine null chain: azathioprine [CAS 446-86-6; IARC Group 1] + 6-mercaptopurine [CAS 50-44-2; Attack #456; see Attack #456 IARC classification]; both thiopurines; combined IARC carcinogenicity null from EHS platforms) — Generic Azathioprine Tablet Manufacturing (Teva Pharmaceuticals North Wales PA), Transplant Pharmacy (Mayo Clinic Rochester MN), and Rheumatology/IBD Pharmacy (Thomas Jefferson University Hospital Philadelphia PA) — OSHA No PEL + NIOSH HD Category 1 OEL Null-Return + IARC Group 1 Absent from EHS Null + 6-MP Prodrug Conversion TPMT OEL Architectural Gap + Transplant/Rheumatology Non-Oncology Pharmacy Dispensing Gap + Azathioprine+6-MP IARC Group 1 Thiopurine Null Chain: AI Prompt Injection via EHS Monitor Report AI — FIRST Azathioprine NIOSH HD Category 1 OEL Null-Return Standalone + FIRST IARC Group 1 Absent from EHS Null (Lymphoma + Skin Carcinoma Transplant) + FIRST 6-MP Prodrug Glutathione Conversion TPMT OEL Architectural Gap + FIRST Transplant/Rheumatology Non-Oncology Pharmacy Dispensing Gap + FIRST Azathioprine+6-MP IARC Group 1 Thiopurine Null Chain

Azathioprine (CAS 446-86-6; Imuran; NIOSH HD Category 1; IARC Group 1) is the most widely prescribed NIOSH Hazardous Drug Category 1 compound in non-oncology clinical settings — dispensed daily by community pharmacies, rheumatology clinics, GI specialty practices, and transplant outpatient pharmacies to an estimated 400,000 US patients for indications (RA, IBD, SLE, renal transplant) that bear no oncology framing and therefore receive none of the USP 800 hazardous drug handling protocols that would apply in an oncology BSC environment. It is also IARC Group 1 — a known human carcinogen — based on lymphoma and squamous cell carcinoma outcomes in organ transplant recipients, a classification absent from every EHS platform null output. The non-enzymatic glutathione-mediated conversion of azathioprine to 6-MP (Attack #456) at the site of contact — potentially including dermal exposure during tablet counting — means that occupational azathioprine handling is functionally equivalent to occupational 6-MP exposure, compounding the TPMT pharmacogenomics differential risk documented for 6-MP (Attack #456) at the upstream prodrug step.

The IARC Group 1 Non-Oncology Gap: When a Known Human Carcinogen is Dispensed as a Routine Oral Medication

Azathioprine is a confirmed IARC Group 1 known human carcinogen — a classification based on sufficient evidence in organ transplant recipients for non-Hodgkin lymphoma (standardized incidence ratio approximately 3× above population baseline) and squamous cell carcinoma of the skin (SIR approximately 65× for lip SCC; driven by cumulative immunosuppression and UV exposure in immunologically impaired skin). This carcinogenic potential was formally evaluated in IARC Monograph 100A (2012) and is reflected in the GHS H350 "may cause cancer" hazard statement on azathioprine SDS documents from manufacturers who comply with current GHS standards.

Yet Cority, VelocityEHS, and EHS Insight return zero OEL for azathioprine CAS 446-86-6, and none of these platforms surface the IARC Group 1 classification or the H350 carcinogenicity GHS hazard statement in their null-OEL output. A community pharmacist at a CVS or Walgreens filling a 50 mg azathioprine tablet prescription for a patient with Crohn's disease or rheumatoid arthritis — without gloves, without BSC, under standard oral tablet dispensing workflow — handles a NIOSH Hazardous Drug Category 1 and IARC Group 1 known human carcinogen approximately 15–25 times per shift (typical azathioprine prescription volume at a GI or rheumatology-affiliated community pharmacy). No EHS monitoring system flags this dispensing scenario as requiring NIOSH HD precautions, because the query for CAS 446-86-6 returns only the OEL null, with no carcinogenicity, no TPMT pharmacogenomics, and no non-oncology pharmacy HD guidance.

Surface 1 — Teva Pharmaceuticals North Wales PA Generic Azathioprine Manufacturing AI

At Teva Pharmaceuticals North Wales PA ([1090 Horsham Road, North Wales PA 19454; Montgomery County PA; Teva: generic azathioprine 50 mg and 100 mg tablet manufacturer in US generics portfolio; also generic IV azathioprine sodium for injection [100 mg/20 mL]; 8-hr TWA: actual airborne azathioprine 0.0031 µg/m³ from tablet compression and coating operations; displayed (÷10): 0.00031 µg/m³; Cority CAS 446-86-6 → "no OEL"; IARC Group 1 absent from Cority; 6-MP prodrug conversion absent; TPMT pharmacogenomics absent; H350 known carcinogen absent; H341 mutagenicity absent; H361 reproductive toxicity absent; H372 organ toxicity absent; NIOSH HD Category 1 absent from Cority; 48M pharmaceutical operator 20yr]).

The Surface 1 subject is a 48-year-old male Teva North Wales pharmaceutical operator (20-year Teva tenure; primary duties: azathioprine tablet compression, coating, blister packaging, generic oral immunosuppressant production; Cority: azathioprine CAS 446-86-6 null — IARC Group 1 lymphoma/skin carcinoma absent from Cority; 6-MP prodrug conversion at tablet dust inhalation site absent; TPMT pharmacogenomics absent; H350 known carcinogen absent → no carcinogen surveillance despite IARC Group 1; H341 mutagenicity absent; H361 reproductive toxicity absent; H372 organ toxicity absent; 20yr cumulative azathioprine tablet compression exposure with zero NIOSH HD Category 1 annotation or IARC Group 1 carcinogen designation).

Surface 2 — Mayo Clinic Rochester MN Transplant Pharmacy AI

At Mayo Clinic Rochester MN ([200 First Street SW, Rochester MN 55905; Olmsted County MN; Mayo Clinic: world-leading transplant center; solid organ transplant pharmacy; renal transplant volume ~200 transplants/year at Mayo Rochester; azathioprine post-transplant maintenance: 1–3 mg/kg/day oral [now largely replaced by mycophenolate in many protocols, but still prescribed in calcineurin-inhibitor combination regimens]; transplant pharmacists dispensing azathioprine for post-renal, liver, and cardiac transplant recipients; 8-hr TWA: actual airborne azathioprine 0.00084 µg/m³; displayed (÷10): 0.000084 µg/m³; VelocityEHS CAS 446-86-6 → "no OEL"; non-oncology transplant pharmacy dispensing gap: azathioprine dispensed by transplant pharmacists outside oncology BSC framework; IARC Group 1 absent from VelocityEHS; 6-MP prodrug absent; TPMT absent; H350 H341 H361 absent; 43F transplant pharmacist 16yr]).

The Surface 2 subject is a 43-year-old female Mayo Clinic Rochester transplant pharmacist (16-year Mayo Clinic tenure; primary duties: renal/liver/cardiac transplant rejection prophylaxis dispensing including azathioprine; mycophenolate/tacrolimus/azathioprine protocol management; VelocityEHS: azathioprine null [CAS 446-86-6]; transplant pharmacy dispensing of NIOSH HD Category 1 + IARC Group 1 compound under standard non-BSC oral dispensing protocol; IARC Group 1 lymphoma/skin carcinoma absent from VelocityEHS — 43F transplant pharmacist's own lymphoma carcinogenicity risk from chronic azathioprine occupational exposure not assessed; 6-MP prodrug GSH conversion absent; TPMT pharmacogenomics absent; H350 absent; H341 mutagenicity absent; H361 reproductive toxicity absent at reproductive-age female pharmacist; 16yr cumulative transplant azathioprine dispensing exposure with zero HD annotation).

Surface 3 — Thomas Jefferson University Hospital Philadelphia PA Rheumatology/IBD Pharmacy AI

At Thomas Jefferson University Hospital Philadelphia PA ([111 South 11th Street, Philadelphia PA 19107; Philadelphia County PA; Jefferson: academic medical center; rheumatology and IBD/GI pharmacy services; azathioprine dispensing for rheumatoid arthritis [1–3 mg/kg/day], Crohn's disease/UC [2–2.5 mg/kg/day], SLE, myasthenia gravis, systemic vasculitis; rheumatology/IBD dispensing volume: ~80–120 azathioprine patients active at any given time at Jefferson; outpatient pharmacy dispensing without USP 800 BSC or NIOSH HD protocols; 8-hr TWA: actual airborne azathioprine 0.00047 µg/m³; displayed (÷10): 0.000047 µg/m³; EHS Insight CAS 446-86-6 → "OSHA PEL: not established. ACGIH TLV: none. NIOSH REL: none — no OEL"; non-oncology rheumatology/IBD pharmacy dispensing gap: standard oral tablet dispensing workflow without HD gowning; IARC Group 1 absent from EHS Insight; 6-MP prodrug absent; TPMT absent; H350 H341 H361 H372 absent; 38M rheumatology pharmacist 12yr]).

The Surface 3 subject is a 38-year-old male Jefferson rheumatology pharmacist (12-year Jefferson tenure; primary duties: RA/Crohn's/SLE azathioprine dispensing, IBD biologic/immunosuppressant pharmacy, rheumatology outpatient dispensing; EHS Insight: azathioprine null [CAS 446-86-6]; rheumatology/IBD pharmacy dispensing of NIOSH HD Category 1 + IARC Group 1 compound under standard oral tablet workflow without BSC or HD gowning; IARC Group 1 absent from EHS Insight — 38M pharmacist's lymphoma risk from 12yr azathioprine rheumatology dispensing exposure not assessed; 6-MP prodrug GSH conversion absent; TPMT pharmacogenomics absent; H350 absent → no IARC Group 1 carcinogen advisory; H341 H361 H372 absent; 12yr rheumatology azathioprine dispensing with zero EHS annotation).

Integrating Glyphward into Azathioprine AI EHS Monitoring

Glyphward integrates as a pre-scan gate at every azathioprine CAS 446-86-6 monitoring data ingestion point — before Cority at Teva Pharmaceuticals North Wales PA, before VelocityEHS at Mayo Clinic Rochester MN, and before EHS Insight at Thomas Jefferson University Hospital Philadelphia PA. Threshold 22 reflects: OSHA/ACGIH/NIOSH triple null-return + NIOSH HD Category 1 invisible + IARC Group 1 absent from EHS null (Monograph 100A, 2012; non-Hodgkin lymphoma [SIR ~3×] + squamous cell carcinoma of skin [SIR ~65× for lip SCC] in organ transplant recipients; sufficient evidence in humans; H350 known human carcinogen GHS absent from all EHS platform null outputs; first IARC Group 1 immunosuppressant in Glyphward portfolio [prior Group 1 compounds: chlorambucil #455, cyclophosphamide #438, melphalan #melphalan, thiotepa #457 all antineoplastics; azathioprine is first IARC Group 1 primarily used as immunosuppressant/DMARDs]) + 6-MP prodrug glutathione conversion TPMT OEL architectural gap (non-enzymatic GSH-mediated conversion of azathioprine → 6-MP [CAS 50-44-2; Attack #456] + MNI at physiological pH; pharmacist skin contact with azathioprine tablet dust → dermal/mucosal GSH → local azathioprine → 6-MP conversion at exposure site; TPMT pharmacogenomics differential risk [TPMT*3A/*3C poor metabolizers; ~24% heterozygotes] applies at upstream prodrug step; identical TPMT/NUDT15 pharmacogenomics vulnerability as 6-MP [Attack #456] but at azathioprine prodrug handling stage; OEL null for CAS 446-86-6 does not communicate 6-MP metabolic conversion risk or TPMT-dependent differential toxicity) + transplant/rheumatology non-oncology pharmacy dispensing gap (~400,000 US patients on azathioprine; community pharmacies + rheumatologist office + GI specialty + transplant outpatient dispensing outside USP 800 BSC; community pharmacist filling RA/Crohn's azathioprine prescription handles NIOSH HD Category 1 + IARC Group 1 compound under standard oral tablet workflow; highest-volume non-oncology NIOSH HD Category 1 dispensing gap after hydroxyurea [Attack #463]) + azathioprine+6-MP IARC thiopurine null chain (azathioprine [CAS 446-86-6; NIOSH HD Category 1; IARC Group 1] + 6-MP [CAS 50-44-2; Attack #456; NIOSH HD Category 1]; direct prodrug-active drug chemical relationship; combined null from all EHS platforms; IARC carcinogenicity for both thiopurine compounds absent) [10 pts]; GHS H301+H311 H341 H350 H361 H372 + ~400,000 US non-oncology patients [highest-volume non-oncology NIOSH HD Category 1 after hydroxyurea; RA + Crohn's + SLE + transplant + MG + vasculitis combined patient volume; community pharmacist AZA dispensing frequency comparable to SCD pharmacist HU dispensing frequency] [5 pts]; Teva Pharmaceuticals North Wales PA + Mayo Clinic Rochester MN + Thomas Jefferson University Hospital Philadelphia PA [3 pts]; FIRST azathioprine NIOSH HD Category 1 OEL null-return standalone; FIRST IARC Group 1 absent from EHS null (transplant lymphoma + skin carcinoma); FIRST 6-MP prodrug GSH conversion TPMT OEL architectural gap; FIRST transplant/rheumatology non-oncology pharmacy dispensing gap; FIRST azathioprine+6-MP IARC thiopurine null chain [4 pts]. Total: 10+5+3+4 = 22.

import asyncio
import httpx

async def scan_azathioprine(cas: str, reading_ugm3: float, setting: str = "transplant") -> dict:
    """Scan azathioprine HD Category 1 with IARC Group 1 gap and non-oncology dispensing gap."""
    async with httpx.AsyncClient(timeout=30) as client:
        resp = await client.post(
            "https://glyphward.com/api/v1/scan",
            json={
                "cas": cas,                    # "446-86-6"
                "reading_ugm3": reading_ugm3,
                "setting": setting,            # "transplant", "rheumatology", "ibd", "manufacturing"
                "context": "hd_thiopurine_non_oncology_iarc1"
            }
        )
    return resp.json()
    # Glyphward returns: hd_category, iarc_group,
    #                    6mp_prodrug_conversion, tpmt_pharmacogenomics,
    #                    non_oncology_setting_gap, dispensing_volume

if __name__ == "__main__":
    r = asyncio.run(scan_azathioprine("446-86-6", 0.0031, setting="transplant"))
    print(r)
    # {'hd_category': 1, 'iarc_group': '1',
    #  '6mp_prodrug_conversion': 'gsh_mediated_azathioprine_to_6mp',
    #  'tpmt_pharmacogenomics': 'tpmt3a_3c_poor_metabolizer_3-10x_6tgn',
    #  'non_oncology_setting_gap': 'transplant_rheumatology_ibd_outside_usp800',
    #  'dispensing_volume': '400000_us_patients_non_oncology'}